News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
704,223 Results
Type
Article (41778)
Company Profile (329)
Press Release (662116)
Section
Business (210112)
Career Advice (2072)
Deals (36570)
Drug Delivery (96)
Drug Development (82779)
Employer Resources (171)
FDA (16475)
Job Trends (15352)
News (355349)
Policy (33816)
Tag
Academia (2574)
Alliances (51054)
Alzheimer's disease (1240)
Approvals (16398)
Artificial intelligence (135)
Bankruptcy (362)
Best Places to Work (11653)
Biotechnology (214)
Breast cancer (118)
Cancer (1044)
Cardiovascular disease (89)
Career advice (1735)
Cell therapy (218)
Clinical research (65615)
Collaboration (364)
Compensation (190)
COVID-19 (2597)
C-suite (89)
Data (1024)
Diabetes (152)
Diagnostics (6210)
Earnings (86387)
Employer resources (149)
Events (112116)
Executive appointments (281)
FDA (16976)
Funding (325)
Gene therapy (176)
GLP-1 (605)
Government (4441)
Healthcare (18843)
Infectious disease (2679)
Inflammatory bowel disease (107)
Interviews (320)
IPO (16557)
Job creations (4050)
Job search strategy (1485)
Layoffs (431)
Legal (8316)
Lung cancer (162)
Manufacturing (175)
Medical device (13250)
Medtech (13255)
Mergers & acquisitions (20053)
Metabolic disorders (407)
Neuroscience (1503)
NextGen Class of 2024 (6623)
Non-profit (4512)
Northern California (1401)
Obesity (236)
Opinion (202)
Patents (100)
People (58149)
Pharmaceutical (92)
Phase I (20289)
Phase II (28867)
Phase III (21671)
Pipeline (407)
Postmarket research (2643)
Preclinical (8647)
Radiopharmaceuticals (239)
Rare diseases (208)
Real estate (6238)
Regulatory (22328)
Research institute (2357)
Resumes & cover letters (358)
Southern California (1245)
Startups (3710)
United States (12956)
Vaccines (566)
Weight loss (180)
Date
Today (205)
Last 7 days (997)
Last 30 days (3626)
Last 365 days (36026)
2024 (32311)
2023 (40628)
2022 (51797)
2021 (56331)
2020 (54795)
2019 (47400)
2018 (35773)
2017 (33138)
2016 (32662)
2015 (38616)
2014 (32516)
2013 (27631)
2012 (29729)
2011 (30487)
2010 (28498)
Location
Africa (776)
Arizona (197)
Asia (39938)
Australia (6384)
California (3144)
Canada (1240)
China (240)
Colorado (140)
Connecticut (143)
Europe (85027)
Florida (428)
Georgia (109)
Illinois (338)
Indiana (198)
Kansas (96)
Maryland (563)
Massachusetts (2523)
Michigan (152)
Minnesota (266)
New Jersey (914)
New York (916)
North Carolina (701)
Northern California (1401)
Ohio (132)
Pennsylvania (806)
South America (1157)
Southern California (1245)
Texas (434)
Washington State (352)
704,223 Results for "lexicon pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Adcomms
Lexicon Loses FDA Adcomm Vote on Insulin Adjunct for Patients With Type 1 Diabetes
While an FDA advisory committee saw signals of efficacy for Lexicon Pharmaceuticals’ sotagliflozin, the panel of external experts found that the company did not provide enough data to support its drug application.
November 1, 2024
·
2 min read
·
Tristan Manalac
Lone Star Bio
Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies Global Healthcare Conference.
May 29, 2024
·
2 min read
Lone Star Bio
Lexicon Pharmaceuticals to Host 2024 Investor Day
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that senior company executives will be joined by leading physicians at the Lexicon 2024 Investor Day on April 22, 2024.
April 18, 2024
·
3 min read
Lone Star Bio
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
Lexicon Pharmaceuticals, Inc. announced its participation in the Bank of America Securities Healthcare Conference 2024. Jeff Wade, Lexicon’s president and chief financial officer, will make a company presentation on Tuesday, May 14, 2024, at 8:00 am PDT.
May 9, 2024
·
2 min read
Lone Star Bio
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that, following multiple interactions with and recent feedback from the U.S. Food and Drug Administration (FDA), it has resubmitted its New Drug Application (NDA) for sotagliflozin as an adjunct to insulin therapy for glycemic control in people with type 1 diabetes and chronic kidney disease (CKD).
June 21, 2024
·
4 min read
Press Releases
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference
November 6, 2024
·
2 min read
Lone Star Bio
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, and Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer, will participate in a moderated discussion at the 23rd Annual Needham Virtual Healthcare conference Wednesday April 10th, 1:30-2:10pm.
April 3, 2024
·
2 min read
Press Releases
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
November 13, 2024
·
15 min read
Business
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2024 and provided an update on key corporate milestones.
May 2, 2024
·
15 min read
Business
Lexicon Pharmaceuticals Selects Medidata to Help Advance First Non-Opioid Drug for Neuropathic Pain in Over Two Decades
Medidata announced today that it has been selected by Lexicon Pharmaceuticals, Inc . to help advance PROGRESS, a Phase 2b study of LX9211 in diabetic peripheral neuropathic pain (DPNP).
May 29, 2024
·
5 min read
1 of 70,423
Next